JP2025523369A5 - - Google Patents
Info
- Publication number
- JP2025523369A5 JP2025523369A5 JP2024570461A JP2024570461A JP2025523369A5 JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5 JP 2024570461 A JP2024570461 A JP 2024570461A JP 2024570461 A JP2024570461 A JP 2024570461A JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5
- Authority
- JP
- Japan
- Prior art keywords
- product according
- pharmaceutical product
- index
- domain variant
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263347939P | 2022-06-01 | 2022-06-01 | |
| US63/347,939 | 2022-06-01 | ||
| PCT/US2023/067697 WO2023235754A1 (en) | 2022-06-01 | 2023-05-31 | Combination therapies for treating urothelial carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025523369A JP2025523369A (ja) | 2025-07-23 |
| JP2025523369A5 true JP2025523369A5 (enExample) | 2026-05-07 |
Family
ID=87036781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024570461A Pending JP2025523369A (ja) | 2022-06-01 | 2023-05-31 | 尿路上皮癌腫を治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010701A1 (enExample) |
| EP (1) | EP4532548A1 (enExample) |
| JP (1) | JP2025523369A (enExample) |
| KR (1) | KR20250022059A (enExample) |
| CN (1) | CN119497722A (enExample) |
| AU (1) | AU2023281712A1 (enExample) |
| CA (1) | CA3253030A1 (enExample) |
| IL (1) | IL316971A (enExample) |
| MX (1) | MX2024014744A (enExample) |
| WO (1) | WO2023235754A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX347954B (es) | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| AU2017250029C1 (en) | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| JP7179743B2 (ja) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| CN110958888A (zh) | 2017-03-28 | 2020-04-03 | 延龄草治疗公司 | Cd47阻断疗法 |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| CN118271443A (zh) | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
| CN121243368A (zh) * | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
-
2023
- 2023-05-31 US US18/326,847 patent/US20240010701A1/en active Pending
- 2023-05-31 AU AU2023281712A patent/AU2023281712A1/en active Pending
- 2023-05-31 CN CN202380052100.6A patent/CN119497722A/zh active Pending
- 2023-05-31 IL IL316971A patent/IL316971A/en unknown
- 2023-05-31 CA CA3253030A patent/CA3253030A1/en active Pending
- 2023-05-31 EP EP23734867.7A patent/EP4532548A1/en active Pending
- 2023-05-31 JP JP2024570461A patent/JP2025523369A/ja active Pending
- 2023-05-31 KR KR1020247042025A patent/KR20250022059A/ko active Pending
- 2023-05-31 WO PCT/US2023/067697 patent/WO2023235754A1/en not_active Ceased
-
2024
- 2024-11-28 MX MX2024014744A patent/MX2024014744A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025523369A5 (enExample) | ||
| JP2023503943A5 (enExample) | ||
| JP2023528341A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| JP7729778B2 (ja) | Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体 | |
| JP2020520370A5 (enExample) | ||
| JP2021526512A5 (enExample) | ||
| JP2024520902A5 (enExample) | ||
| JP2018134080A (ja) | イムノコンジュゲートを作製する抗体を修飾するための特定部位 | |
| JP2007500236A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2008530142A5 (enExample) | ||
| JP2019530434A5 (enExample) | ||
| JP2011507932A5 (enExample) | ||
| JP2003531129A5 (enExample) | ||
| JP2004512262A5 (enExample) | ||
| Govindan et al. | New antibody conjugates in cancer therapy | |
| WO2022155541A1 (en) | Interferon prodrugs and methods of making and using the same | |
| IL274122B2 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2022534212A5 (enExample) | ||
| JP2021501776A5 (enExample) | ||
| JP2020515577A5 (enExample) | ||
| JP2019524713A5 (enExample) | ||
| JP2024510142A5 (enExample) | ||
| WO2022268050A1 (zh) | 一种药物组合及其用途 |